60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.440
0.00 (0.00%)
Sep 17, 2025, 9:30 AM EDT - Market open
SXTP Revenue
60 Degrees Pharmaceuticals had revenue of $307.87K in the quarter ending June 30, 2025, with 144.93% growth. This brings the company's revenue in the last twelve months to $984.49K, up 128.70% year-over-year. In the year 2024, 60 Degrees Pharmaceuticals had annual revenue of $681.35K with 168.70% growth.
Revenue (ttm)
$984.49K
Revenue Growth
+128.70%
P/S Ratio
1.54
Revenue / Employee
$328,165
Employees
3
Market Cap
5.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 681.35K | 427.77K | 168.70% |
| Dec 31, 2023 | 253.57K | -257.64K | -50.40% |
| Dec 31, 2022 | 511.21K | -5.84M | -91.95% |
| Dec 31, 2021 | 6.35M | 3.80M | 149.18% |
| Dec 31, 2020 | 2.55M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SXTP News
- 14 days ago - 60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 27 days ago - 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis - GlobeNewsWire
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering - GlobeNewsWire
- 2 months ago - 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format - GlobeNewsWire